RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

NCT05154344 · clinicaltrials.gov ↗

COMPLETED

Status

182

Enrollment

OTHER

Sponsor class

Conditions

MET Alterations
Non Small Cell Lung Cancer
METex14 Mutations

Interventions

DRUG: Capmatinib

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Collaborators

[object Object]